RxDoctor Payments Data

James Rotolo, MD

Urology · Brick, NJNPI 1588635916

Payments from drug & device makers

$2,087in general payments, 2019–2025

Across 110 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$558
  • Pfizer$452
  • Johnson & Johnson$230
  • Medtronic$198
  • Tolmar, Inc.$117
  • Myovant Sciences Inc.$106
  • plus $425 from 12 others

What the payments were for

  • Food & beverage$1,68080%
  • Education$40720%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,087 in reported general payments places this provider in the 45th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$262,811
Medicare patients
806
Services billed
2,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide32$477,639
MyrbetriqMirabegron97$73,535
GemtesaVibegron55$39,719
ElmironPentosan Polysulfate Sodium11$22,330
Tamsulosin Hcl794$20,171
Finasteride364$6,768
Silodosin91$6,547
Trimethoprim50$4,059
Fesoterodine Fumarate ErFesoterodine Fumarate27$2,803
Tolterodine Tartrate ErTolterodine Tartrate40$2,550
NitrofurantoinNitrofurantoin Macrocrystal52$2,065
Oxybutynin Chloride ErOxybutynin Chloride43$1,205
Methenamine Hippurate22$814
Bicalutamide13$658
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst40$656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$558$551,174129 claims
Sumitomo Pharma America, Inc.Gemtesa$13$39,71955 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 401 urology providers in New Jersey.

Other urology in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →